Ipsen (IPN.PA) Announces A First Set Of Results On Positive Phase III Clinical Study Of Dysport® In The Treatment Of Adults Suffering From Upper Limb Spasticity At The 8th World Congress For Neurorehabilitation In Istanbul
4/14/2014 9:38:54 AM
PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that a first set of results on phase III clinical study of Dysport® in the treatment of adults suffering from Upper Limb Spasticity was presented on Saturday, April 12th, at the 8th World Congress for NeuroRehabilitation in Istanbul (Turkey).
Help employers find you! Check out all the jobs and post your resume.
comments powered by